OBJECTIVES: To address the safety (rate of thromboembolic events and circuit complications) and efficacy (rate of bleeding control) of recombinant activated coagulation factor VII (rFVIIa) to treat severe bleeding refractory to all surgical and medical treatments in patients under veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support.
INTRODUCTION
Haemorrhagic complications are common among patients under veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO) treatment for cardiac and/or pulmonary failure. On one hand, the rate of clinically significant haemorrhagic events depends on the indication to ECMO, being particularly increased in post-cardiotomy patients (up to 58% rate of rethoracotomy to treat major mediastinal bleeding) [1] . On the other hand, ECMO therapy itself facilitates the occurrence of bleeding complications through induction of coagulopathy (acquired von Willebrand syndrome [2] and consumption of coagulation factors [3] ) and through the administration of anticoagulant therapy while treatment is ongoing, as currently recommended [4] .
Haemorrhagic complications may be life-threatening in a significant proportion of these patients. Optimal surgical treatment, temporary withdrawal of anticoagulant therapy, substantial transfusion of blood products and optimization of metabolic conditions may be insufficient to stop bleeding in some cases. In such rare yet problematic patients, the administration of recombinant activated coagulation factor VII (rFVIIa) has been proposed as an off-label, salvage therapy (NovoSeven, Novo Nordisk, Copenhagen, Denmark). Concerns have been raised concerning the safety of such an approach, given the risk of thromboembolic events and of ECMO circuit dysfunction. Fatal thrombotic events have been reported in paediatric patients on VA ECMO following correction of congenital heart disease [5, 6] . The largest previous series of adult patients receiving rFVIIa while on ECMO includes 15 cases [7] , and suggested the relative safety of rFVIIa administration in these circumstances. Nonetheless, no definitive demonstration of survival gain owing to rFVIIa administration could be provided.
The objective of the present study was to report the clinical results in a larger series (N = 30) of patients receiving rFVIIa during ECMO treatment, and to formally compare the rate of thromboembolic events with a cohort of matched ECMO patients, in order to ascertain the safety of rFVIIa use in these patients. Secondly, we aimed at defining the efficacy of rFVIIa in limiting the bleedingrelated mortality in these individuals.
PATIENTS AND METHODS

Patient selection
We retrospectively queried our electronic database to identify the adult patients who received at least one dose of rFVIIa for bleeding refractory to all other therapies while on VA or VV ECMO therapy from January 2005 to March 2014. All patients were treated at a single institution within three distinct intensive care units (ICUs; general medical ICU, general surgical ICU and dedicated cardiac surgery ICU). Administration of rFVIIa before ECMO implantation or after its explantation was an exclusion criterion. Since the beginning of the ECMO programme at our institution, the clinical data of all patients receiving such treatment are prospectively included into an electronic database by dedicated research nurses. Baseline pre-implantation, post-implantation and late clinical information are included. The database is regularly checked for completeness and consistency. Indication to ECMO therapy was considered in compliance with the current recommendations [4] , and patients on treatment were evaluated on a daily basis by a multidisciplinary team consisting of two physicians (cardiologist and anaesthesiologist) and one surgeon in all cases. Similarly, the indication to the employment of rFVIIa was decided by consensus after multidisciplinary discussion. Life-threatening bleeding of any origin (not limited to the post-cardiothoracic surgery settings) persisting after optimal surgical/endovascular therapy and after adequate correction of coagulation disorders was a potential indication to rFVIIa administration. All patients but one underwent at least one open surgical revision in order to control bleeding; 1 case of persisting bleeding from the bronchial tree did not receive open surgery but had endobronchial fibroscopy instead. To achieve the maximal efficacy of rFVIIa, transfusion of blood products ( packed red blood cells, pRBC; platelets, PLT; fresh frozen plasma, FFP; cryoprecipitate) was performed in order to achieve a target haematocrit >24%, platelet concentration >50 000/ml, prothrombin time >50%, activated partial thromboplastin time ratio <2 and fibrinogen content >100 mg/dl. Hypothermia and hypocalcaemia were also corrected before considering rFVIIa employment. Heparin administration was also interrupted during full-flow ECMO support as an additional measure to correct bleeding. The rFVIIa was available at our institution since the beginning of ECMO programme in 2005. One first administration of rFVIIa at a dose of 60 µg/kg was performed in all cases. After rFVIIa administration and in any case after interruption of heparin infusion, care was taken to maintain optimal ECMO flow in order to minimize the risk of circuit thrombosis.
Materials and surgical technique
The ECMO therapy was implanted by a surgical team including one senior surgeon, one resident surgeon, one scrub nurse and one perfusionist in all cases, as previously described [8] .
The most common vascular access for VA ECMO implantation was peripheral (92%). After a longitudinal incision at the groin, the anterior aspect of the common femoral artery and vein was prepared and cannulated according to the Seldinger technique (16) (17) (18) (19) (20) Fr for the inflow cannula and 18-32 Fr for the drainage cannula, according to the patient's body surface area, vessels' quality and surgeon's preference; Edwards Lifesciences, Inc., Irvine, CA, USA). In all peripheral cases, a reperfusion catheter was introduced in the superficial femoral artery to prevent limb ischaemia (5-10 Fr). Two patients received central VA ECMO implantation in post-cardiotomy settings.
Among patients receiving VV ECMO therapy, this was established through percutaneous cannulation of the right femoral (drainage) and jugular (re-injection) veins (Edwards Lifesciences, Inc.,) using the Seldinger technique. Adequate positioning of the cannulae was checked by chest X-rays and by transthoracic/ transoesophageal echocardiography. As a general protocol, patients received a bolus of 5000 units of unfractionated heparin immediately before cannulation (if not already heparinized) and intravenous heparin in order to maintain an activated clotting time between 150 and 180 s. In the presence of haemorrhagic complications (or in the immediate post-cardiotomy settings), heparin administration was adjusted or withheld. Pump speed was corrected to obtain a cardiac index within the 2.2-to 2.8-ml/min/m 2 range with adequate cardiac decompression; care was taken to obtain the opening of the aortic valve during VA ECMO support in order to minimize the risk of pulmonary oedema and of thromboembolism. In the event of pulmonary oedema and inadequate left heart decompression, placement of intra-aortic balloon counterpulsation (IABP) with adjustment of inotropic drugs was considered. Magnetic centrifugal pumps (Maquet Rotaflow® or Cardiohelp® devices) with a heparin-coated circuit and a Quadrox® oxygenator (Maquet, Inc., Hirrlingen, Germany) were used.
Definitions and follow-up
For the purposes of the present paper, we adopted the terminology employed in the current guidelines [4] . Adverse events on VA or VV ECMO therapy were defined according to the Extracorporeal Life Support Organization (ELSO) Registry [9] . For the purposes of the present investigation, the rate of any thromboembolic event (including central nervous system or peripheral embolism, intravascular thrombus at any site and pulmonary embolism) and that of ECMO circuit dysfunction (circuit/oxygenator thrombosis leading to haemolysis and/or circuit exchange) were noted. Patients were evaluated using the simplified acute physiology score (SAPS) version 2 immediately before ECMO implantation [10] and using the calculator available online at www.sfar.org (website of the French Society of Anesthesia and Intensive Care).
For the performance of follow-up investigation, survivors at hospital discharge were periodically contacted telephonically by research nurses experienced in the management of patients treated by mechanical circulatory support. Inquiries included the patients' vital status, functional classification and occurrence of late complications. In case of impossibility to get in touch with the patients, the general practitioners and/or the referring cardiologists were contacted. Follow-up data were included in the Rennes prospective ECMO registry.
Since this investigation was retrospective and did not entail an additional diagnostic or therapeutic procedure other than stateof-the-art care and since all data were treated anonymously, patients' consent to enter the study was waived. Additionally, the institutional electronic database is declared online to the CLIN [Commission Nationale de l'Informatique et des Libertées (National Committee for Informatics and Freedom)] under the dossier number 1207754, in accordance with the French law. Approval from the local ethical committee was obtained.
Endpoints
(i) The primary safety endpoint was the rate of thromboembolic events in VA and VV ECMO patients receiving rFVIIa for intractable bleeding, and the rate of ECMO circuit complications (including the need for circuit/oxygenator exchange) in patients receiving rFVIIa for intractable bleeding. (ii) The secondary safety endpoint was the comparison of early and late clinical results among case-matched ECMO patients receiving rFVIIa versus those who required no treatment with rFVIIa. (iii) The primary efficacy endpoint was the rate of control of refractory and life-threatening bleeding after administration of rFVIIa during ECMO support (according to the definitions that follow). (iv) The secondary efficacy endpoint was the amount of transfused blood products before and after rFVIIa administration, and the rate of survival to hospital discharge in the same patients' population.
For the purposes of definition of effectiveness, the amount of bleeding (output of chest tubes and/or other drains) was calculated in ml during the 12 h before the first rFVIIa infusion and during the first 12 h after infusion, and averaged per hour. Control of bleeding was defined as complete (whether the hourly bleeding after rFVIIa infusion was lower than 50 ml), partial (hourly bleeding comprised a volume between 50 and 100 ml) and absent (hourly bleeding greater than 100 ml during the first 12 h post-infusion).
Statistical analysis
Continuous data are presented as mean ± standard deviation and categorical variables as frequencies and percentages. Median and 25th-75th percentiles were also provided. Survival analysis was performed according to the Kaplan-Meier method, and corresponding survival curves were plotted. Survivorship between different groups was compared using the log-rank test. In a following substudy, a case-matched analysis (exact matching) was performed on the basis of concordance in the following pre-implantation variables: age (<65 or ≥65 years), indication to ECMO ( post-cardiotomy, postheart transplantation and other indications), gender, VA or VV ECMO, intra-aortic balloon counterpulsation therapy at implantation and biological parameters at the time of implantation (blood haemoglobin <10 vs ≥10 mg/dl, platelet count <100 000 vs ≥100 000/mm 3 and blood pH (<7 vs ≥7). For each patient receiving rFVIIa treatment during ECMO therapy, we searched into our electronic database, and matched patients who shared the same distribution of baseline variables but who received no rFVIIa treatment. Whether more than one match was available from the larger pool of no-rFVIIa patients, all of them were included in the control group. Among 23 rFVIIa patients who could be matched, 20 had two matches and 3 had one match. Therefore, the control group consisted of 43 cases. Matching was done automatically by the statistical analysis software. We could not employ techniques such as the coarsened exact matching or the propensity score matching due to the limited sample size. For intergroup comparison, the two-tailed Mann-Whitney U-test (continuous data and non-normal distribution) and the χ 2 test (categorical data) were employed. Skewness and normality of variables were assessed (Shapiro-Wilk test). The alpha level was 0.05. Analyses were performed using the SAS ver. 9.33 software for Windows (SAS Institute, Inc., Cary, NC, USA).
RESULTS
A total of 30 patients met the inclusion criteria (administration of rFVIIa during ongoing VA or VV ECMO therapy) and were included. These represented 8.6% of the overall ECMO activity at our institution during the same time span (N = 347). The study workflow is reported in Fig. 1 . The baseline descriptors of the 30 patients who received rFVIIa are summarized in Table 1, whereas  Table 2 reports the details of bleeding and the in-hospital clinical results. The majority of patients received VA ECMO, whereas VV ECMO was employed in a minority of cases (10%, N = 3). The most common indication to ECMO treatment was early graft failure (EGF) after heart transplantation (46.6%) or post-cardiotomy for other heart surgery (40%); this is reflected by the distribution of the sites of life-threatening bleeding, which originated from the mediastinum in the vast majority of the cases and represents postoperative bleeding. Other less common sources of bleeding were post-traumatic bleeding from the right carotid and subclavian arteries and spontaneous bleeding from the retroperitoneum and the bronchial tree. One patient was implanted during cardiac arrest refractory to advanced life support and ongoing external cardiac massage. Major requirement for transfusion of blood products was observed in all these patients. ECMO circuit change was required for a total of five times in 4 patients due to haemolysis and fibrin deposits; nonetheless, we observed no cases of severe circuit thrombosis with severe ECMO dysfunction (safety endpoints). Thromboembolic events were reported in only 1 case (non-fatal overt disseminated intravascular coagulation scored 8 according to the Taylor scale [11] ). This episode was complicated by transient paraplegia for which a thromboembolic origin could not be ruled out. Neither were there cases of cerebral stroke nor of gastrointestinal complications. Overall, 67% of patients were alive at the time of ECMO explantation (average ECMO duration: 8.9 ± 7.3 days) and 50% were alive at the 30th post-implantation day. Effectiveness of bleeding control was considered as complete in 18 patients (60%), partial in 8 (27%) and absent in 4 (13%). Hourly bleeding in the complete bleeding control group (as averaged over 12 h) decreased from 295 ± 524 to 42 ± 21 ml/h. In the partial control group, bleeding passed from 359 ± 316 to 89 ± 19 ml/h. In the absent control group, bleeding passed from 310 ± 276 to 345 ± 288 ml/h. Later bleeding control was observed in 2 of the 4 patients included in the absent control group; therefore, lifethreatening bleeding could be finally controlled in all cases but 2 (93.3% efficacy rate). Causes of death were refractory heart failure in 45% of cases (including 36.4% refractory EGF after heart transplantation), sepsis and/or multiorgan failure (36.4%). Persisting haemorrhage despite rFVIIa administration was considered to be a major cause of death in 2 patients. At the time of ECMO explantation, the average blood haemoglobin was 9.8 ± 1.8 g/dl, platelet count was 80 900 ± 32 700 N/mm 3 , blood pH was 7.4 ± 0.1 and serum lactates were 2.1 ± 1.2 mmol/l. The requirements for transfusion of blood products decreased markedly from the 12 h before rFVIIa infusion to the subsequent 12 h (18.2 ± 11-6 ± 4 units; including units of red blood cells concentrate, FFP and platelets).
Substudy: case-matching
At the end of the case-matching procedure, 23 patients who received rFVIIa could be matched to at least 1 patient from the larger pool of individuals who received no rFVIIa but who shared the same baseline characteristics, as detailed above. Groups consisted of 23 patients (Group A, rFVIIa administration) and 43 patients (Group B, controls-no rFVIIa administration). Table 3 reports the intergroup comparison for pre-and post-explantation variables. As expected, the two groups presented comparable overall baseline risk profiles (average SAPS score). There were no statistically significant differences among groups in terms of adverse events during and immediately after ECMO support, remarkably in the rate of thromboembolic events and of the need for circuit change. Survival both at ECMO explantation and at the 30th post-implantation day was also comparable among groups (P = 0.27 and 0.51, respectively). Figure 2 depicts the KaplanMeier survival curves obtained for Group A versus Group B (average follow-up: 101.4 ± 87.4 and 123.2 ± 79 days, respectively). Survival remains globally stable after the 30th post-implantation day. Remarkably, there is no statistically meaningful difference among the two groups (log-rank P = 0.42).
COMMENT
VA and VV ECMO are becoming an increasingly systematized resource for the treatment of patients with severe cardiac, pulmonary and combined failure. Advances in patient selection, ICU protocols and technological improvements have allowed the continued improvement of clinical results during recent years [8, 12, 13] . As it is based on extracorporeal circulation, ECMO may nonetheless be associated with a number of end-organ complications. Among these, both haemorrhagic and thrombotic events still occur at considerable rates [1, 14] . Contact of blood with tubing and oxygenator surfaces is a potent stimulus to clotting; the absence of residual opening of the aortic valve and a dilated, immobile left ventricular cavity in most severe VA ECMO patients may facilitate thrombus development. On the other hand, disruption of coagulation factors, impairment of primary coagulation through acquired von Willebrand syndrome [2] and heparinization during support facilitate haemorrhage. Since ECMO support is required in a remarkable proportion of cases for post-cardiotomy cardiac failure (29% in our centre's overall experience), increased mediastinal bleeding is often observed in these circumstances. In fact, 86.7% of patients included in the present study were on VA support immediately after heart transplantation or other cardiac surgery.
The present investigation was focused on a cohort of particularly complex ECMO patients, i.e. those who were complicated by severe life-threatening spontaneous or surgical bleeding, refractory to all conventional surgical and medical tools to obtain adequate haemostasis. For these cases, the off-label employment of rFVIIa was decided as a rescue measure. rFVIIa directly activates factor X on the surface of activated platelets, leading to downstream generation of a 'thrombin burst' at the site of vascular injury [15, 16] . Initially developed for the treatment of genetic or acquired haemophilia, the first administrations of rFVIIa in patients on ECMO after paediatric cardiac surgery have been marked by considerable rates of thromboembolic events (up to 20%) [5, 6] and of major circuit thrombosis [17] . In the present study, which analyses the largest series so far of adult patients receiving rFVIIa during ECMO support (N = 30), we observed optimal rates of effectiveness (termination of life-threatening bleeding in 93.3% of cases). Two patients presented with continued bleeding despite administration of rFVIIa; in these 2 cases, bleeding was deemed as a major cause of death although other factors may have contributed to fatal multiorgan failure. We also observed limited rates of thromboembolic events (3.3%) and no instances of major circuit thrombosis (safety endpoints). The rate of circuit change was 16.7% for an average support duration exceeding 7 days. ECMO in adult patients is characterized by greater tubing diameter and pump size, greater size of cannulae and higher flow rates than in paediatric systems; these elements may offer a theoretical explanation for the different safety profiles of rFVIIa among adult and paediatric patients. Care was taken in our patients to maintain fullflow support after withdrawal of unfractionated heparin and administration of rFVIIa. The essentially local mechanism of action of rFVIIa (triggered by local platelet activation at the site of vascular disruption) diminishes the risk of generalized activation of the coagulation cascade [18] . Combined administration of rFVIIa and activated prothrombin complex should be anyway prescribed given the risk of massive intravascular coagulation [19] . In our series, the leading causes of death were persisting cardiac failure and multiorgan insufficiency, while brain death was not considered in any case to be the primary cause of mortality. One previous case of uncomplicated rFVIIa administration in a patient with a left ventricular assist device (LVAD) has been reported [20] . Besides this anecdotal report, no evidence exists over the use of rFVIIa in LVAD-assisted patients; such a strategy needs to be carefully validated given the major severity of LVAD thrombosis. Additional caution may be employed in the settings of EGF; 1 case of endocavitary left atrial thrombus has been reported in a patient on VA ECMO after administration of rFVIIa [21] . After heart transplantation, immunological factors may theoretically facilitate thrombus development at the endocardial surface of cardiac grafts [22] .
Safety concerns exist about the use of rFVIIa in adult patients undergoing general cardiac surgery. A randomized study in patients with significant bleeding after cardiac operation reported a lower rate of surgical re-exploration but also a non-significant increase in adverse events (stroke, myocardial infarction, pulmonary embolism or other thrombotic complications) after use of rFVIIa [23] . Similarly, a propensity-matched investigation suggested that employment of rFVIIa is associated with higher rates of mortality and renal complications in patients undergoing complex cardiac surgery [24] . Our study may address safety issues only in the cohort of patients under VA or VV ECMO; nonetheless, we believe that the decision-making over the use of rFVIIa should be discussed case by case in a multidisciplinary fashion, and probably reserved to instances of failure of all conventional therapies. Repessé et al. [7] , based on a clinical experience over 15 patients treated with rFVIIa during ECMO, have been the first to propose an algorithm for the administration of this drug in such patients. Such an algorithm is based on the concept of exhausting any means of biological optimization of patients' coagulation before considering rFVIIa use. We confirm such an approach, since corrections were applied in order to achieve a haematocrit >24%, platelet count >50 000/ml, prothrombin time >50%, activated partial thromboplastin time ratio <2 and fibrinogen content >100 mg/dl before rFVIIa use. Hypothermia, hypocalcaemia and pH were also optimized. Such a strategy is meant not only at avoiding exposing the patient to the risk of thromboembolism, but also at maximizing the efficacy of rFVIIa. Additionally, at least one surgical revision was systematically performed before infusion of rFVIIa. No demonstrated thrombotic event was observed in the series by Repessé and co-workers, although cerebral stroke could not be ruled out in 2 cases of brain death occurring early after rFVIIa administration.
Here, we provided additional evidence of the safety of rFVIIa treatment by means of a case-matched comparison with control patients who received no rFVIIa administration. For such a purpose, cases who did not receive such treatment were selected from the larger pool of in-house ECMO patients, and matched to each rFVIIa-treated individual on the basis of a panel of baseline descriptors and indicators of clinical gravity at the time of ECMO institution. Several of such indicators (age, indication to support and blood pH) have been found in previous studies to determine both early and late outcomes [8] . After matching, Group A patients (those treated with rFVIIa) showed comparable rates of thromboembolic events and of circuit change than Group B individuals (those who received no rFVIIa). The rate of transfusion of FFP was only found to be increased in Group A. This is most likely the expression of severe bleeding in Group A patients and of our strategy based on the correction of any coagulopathy before administration of rFVIIa. Most interestingly, these two groups shared similar rates of major complications and of survival at both ECMO explantation and at the 30th post-implantation day. Main biological parameters at the time of support termination were also superimposable. Such data suggest the safety of rFVIIa use if a strict protocol for patient's preparation and close surveillance are applied. Additionally, the follow-up survival is also comparable among Groups A and B (Kaplan-Meier curves, Fig. 2 ): such a feature echoes the behaviour of 'average' ECMO patients [8] and suggests the absence of late complications after rFVIIa use. This comparison is limited by the unavailability of the 'ideal' control group, i.e. patients who suffered severe refractory bleeding and had no access to rFVIIa, since NovoSeven was available in our centre before the beginning of the VA ECMO programme. Such a control group would optimally address the efficacy endpoint: we cannot derive from our case-matched comparison any conclusions over the effectiveness of rFVIIa in stopping bleeding (although the 93.3% success rate in the overall series appears satisfying). With regard to the safety endpoint, we believe that the currently available comparison provides information under the perspective of the thromboembolic rate (safety endpoint), which was not significantly different among groups. Control patients here did not present with severe refractory bleeding and therefore were not exposed to the associated mortality risk; nonetheless, further studies are needed to confirm that the use of rFVIIa may significantly ameliorate the survival of patients with severe refractory bleeding during ECMO support.
Further limits of the present investigation are represented by the retrospective design (although all data have been prospectively collected) and by the small number of patients entered into the case-matching procedure, which precluded the execution of more advanced pairing methodologies, such as propensity score matching. In particular, the case-control comparison is limited by the unavailability of control patients with severe refractory bleeding and who had no access to rFVIIa. Also, conclusions can be drawn mainly concerning the bleeding secondary to heart transplant or other cardiac surgery. We did not employ rotational thromboelastometry in the evaluation of our patients. This diagnostic tool deserves investigation in patients on ECMO treatment and with severe bleeding, as it might improve the clinical decision-making. Despite these limitations, here we present the largest available series of patients administered with rFVIIa during ECMO therapy. Our data indicate safety and non-inferiority in terms of early and late survival versus matched patients who required no rFVIIa treatment, with comparable early and late results despite most severe general conditions and otherwise refractory bleeding. We conclude that the clinician should not refrain from administering rFVIIa during ECMO (when refractory bleeding threatens the patient's life) out of fear of dramatic thromboembolic events or sudden circuit dysfunction.
